- Home
- URGN vs SATL Comparison
URGN vs SATL Comparison
Compare URGN & SATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- SATL
- Stock Information
- Founded
- URGN 2004
- SATL 2010
- Country
- URGN United States
- SATL United States
- Employees
- URGN N/A
- SATL N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- SATL Radio And Television Broadcasting And Communications Equipment
- Sector
- URGN Health Care
- SATL Technology
- Exchange
- URGN Nasdaq
- SATL Nasdaq
- Market Cap
- URGN 465.9M
- SATL 433.8M
- IPO Year
- URGN 2017
- SATL N/A
- Fundamental
- Price
- URGN $9.67
- SATL $3.89
- Analyst Decision
- URGN Strong Buy
- SATL
- Analyst Count
- URGN 7
- SATL 0
- Target Price
- URGN $37.21
- SATL N/A
- AVG Volume (30 Days)
- URGN 499.1K
- SATL 658.1K
- Earning Date
- URGN 05-12-2025
- SATL 04-29-2025
- Dividend Yield
- URGN N/A
- SATL N/A
- EPS Growth
- URGN N/A
- SATL N/A
- EPS
- URGN N/A
- SATL N/A
- Revenue
- URGN $90,398,000.00
- SATL $12,870,000.00
- Revenue This Year
- URGN $38.65
- SATL N/A
- Revenue Next Year
- URGN $118.69
- SATL N/A
- P/E Ratio
- URGN N/A
- SATL N/A
- Revenue Growth
- URGN 9.29
- SATL 27.75
- 52 Week Low
- URGN $8.94
- SATL $0.72
- 52 Week High
- URGN $20.70
- SATL $5.49
- Technical
- Relative Strength Index (RSI)
- URGN 41.45
- SATL 52.87
- Support Level
- URGN $8.94
- SATL $3.73
- Resistance Level
- URGN $10.83
- SATL $4.22
- Average True Range (ATR)
- URGN 0.79
- SATL 0.40
- MACD
- URGN -0.07
- SATL 0.04
- Stochastic Oscillator
- URGN 29.67
- SATL 58.60
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.